AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1128571
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of cholylglycine at a dose of 5 mumoles per kilogram
Trial: 26236925
Drug: peg-interferon/ribavirin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peg-interferon/ribavirin treatment for 12 weeks followed by 48 weeks for cEVR patients (Group A)
Trial: 26236925
Drug: peg-interferon/ribavirin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peg-interferon/ribavirin treatment for 12 weeks followed by 72 weeks (Group B1)
Trial: 26236925
Drug: peg-interferon/ribavirin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peg-interferon/ribavirin treatment for 12 weeks followed by 96 weeks (Group B2)
Trial: 23179471
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (generic citalopram 20 mg)
Trial: 23179471
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (branded citalopram 20 mg)
Trial: 21502083
Drug: Valganciclovir 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir 900 mg daily for 8 weeks
Trial: 10545787
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) and leucovorin (LV) administered as a 14-day continuous infusion according to a flat or three different chronomodulated rhythms
Trial: 320494
Drug: Dantrium (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dantrium (up to 800 mg for 14‐16 days)
Trial: 25974277
Drug: Control blocks
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control blocks + intravenous (IV) dexamethasone (4 mg)
Trial: 25974277
Drug: Control blocks
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control blocks + IV buprenorphine (150 μg) + IV dexamethasone
Trial: 15046282
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml 30% glucose
Trial: 9776154
Drug: Intraoperative irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative irrigation with 10 mL 0.5% bupivacaine in 500 mL saline
Trial: 28988173
Drug: Topical DPCP
RxNorm normalized name: DPCPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical DPCP therapy for up to 12 months
Trial: 28988173
Drug: Topical imiquimod
RxNorm normalized name: imiquimod Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical imiquimod therapy for up to 12 months
Trial: 16922749
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (500 mug) prior to anaesthesia and postoperative intravenous patient-controlled analgesia with morphine
Trial: 16922749
Drug: Postoperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intravenous patient-controlled analgesia only
Trial: 17848760
Drug: Esmolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (50 microg/kg loading dose followed by 100 microg/kg/hr infusion)
Trial: 17848760
Drug: Diltiazem (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (0.15 mg/kg loading dose followed by 5 mg/hr infusion)
Trial: 22108775
Drug: Rabeprazole 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 40 mg once daily
Trial: 8268118
Drug: Saline (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (control for intravenous fentanyl)
Trial: 3899165
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin pretreatment
Trial: 29359480
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (1000 mg omega-3 fatty acids)
Trial: 27590865
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention (8 weeks of daily sessions)
Trial: 24846347
Drug: Brodalumab (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab (doses between 140 and 210 mg)
Trial: 18076705
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg subcutaneously once weekly for 12 weeks
Trial: 11529652
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg qid
Trial: 7955975
Drug: Acute hypoglycaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute hypoglycaemia in insulin-dependent diabetic patients
Trial: 7955975
Drug: Reference test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference test with normal plasma glucose levels in insulin-dependent diabetic patients
Trial: 3616277
Drug: Type of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type of treatment within the family
Trial: 21733605
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine supplementation (30g/day, 0.41g/kg/day)
Trial: 8412294
Drug: Response Rate
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response Rate to Radiation Therapy in young cohort
Trial: 8412294
Drug: Salvage Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage Therapy Response Rate
Trial: 21311355
Drug: l-Arg HCl
RxNorm normalized name: L-Arg
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: l-Arg HCl (30 g at 0.5 g·min(‐1))
Trial: 18294115
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anticholinergic therapy with alpha1‐antagonists
Trial: 10632419
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) for the first two cycles and human menopausal gonadotropin (hMG) for the last two cycles (CCHH)
Trial: 10632419
Drug: Human menopausal
RxNorm normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human menopausal gonadotropin (hMG) for the first two cycles and clomiphene citrate (CC) for the last two cycles (HHCC)
Trial: 27112041
Drug: Early fortification
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early fortification (EF) starting at 20 mL/kg/d
Trial: 27112041
Drug: Delayed fortification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed fortification starting at 100 mL/kg/d
Trial: 22507335
Drug: Loratadine syrup
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine syrup
Trial: 22507335
Drug: Cyproheptadine HCl
RxNorm normalized name: cyproheptadine HCl
DrugBank: Cyproheptadine (DB00434)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyproheptadine HCl solution
Trial: 20215456
Drug: Standard glycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glycemia treatment
Trial: 9273182
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (ICT) including three cycles of 5-fluorouracil (600 mg/m2/d), cisplatin (15 mg/m2/d), etoposide (50 mg/m2/d), hydroxyurea (1,500 mg/d)
Trial: 9273182
Drug: Concomitant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemotherapy and chest radiotherapy (CCRT) with cisplatin (20 mg/m2) and 5-fluorouracil (500 mg/m2) during radiotherapy
Trial: 8077090
Drug: Lysine clonixinate
RxNorm normalized name: lysine clonixinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine clonixinate (125 mg, 1 or 2 tablets every 8 h for 48 h)
Trial: 8077090
Drug: Paracetamol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (500 mg, 1 or 2 tablets every 8 h for 48 h)
Trial: 31256650
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of intravenous (IV) TXA given prior to the skin incision
Trial: 31256650
Drug: Double-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose regimen of 1 g IV TXA given prior to skin incision and at time of wound closure
Trial: 31256650
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1 g IV TXA given prior to skin incision and 1 g of intraoperative topical TXA
Trial: 31256650
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of 1950 mg oral TXA given two hours preoperatively, six hours postoperatively, and on the morning of postoperative day one
Trial: 28944355
Drug: Immediate placement
RxNorm normalized name: IR DIP 10 1 % Iodine Replacement Teat Dip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate placement of 6.0 to 8.0 mm wide diameter implants (immediate group; 50 patients)
Trial: 28944355
Drug: Delayed placement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed placement of 4.0 or 5.0 mm diameter implants (delayed group; 50 patients)
Trial: 17404896
Drug: Oral bovine
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral bovine collagen
Trial: 12101535
Drug: Intravenous pyelography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pyelography
Trial: 9987703
Drug: Erythromycin 333
RxNorm normalized name: erythromycin 333 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 333 mg
Trial: 9987703
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg
Trial: 2272187
Drug: Sustained-release diclofenac
RxNorm normalized name: diclofenac Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release diclofenac sodium (100 mg)
Trial: 27492799
Drug: Control implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control implants (Osseotite) with dual acid‐etched (DAE) surface in the apical portion and a machined coronal part.
Trial: 27492799
Drug: Test implants
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test implants (Full Osseotite, FOSS) which were completely DAE.
Trial: 27492799
Drug: Both control
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both control and test implants.
Trial: 26647864
Drug: ESM self-monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESM self-monitoring with weekly feedback sessions
Trial: 2751973
Drug: PGF2 alpha‐isopropylester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGF2 alpha‐isopropylester eye drops (1.0 microgram daily or 0.5 microgram twice daily)
Trial: 27277189
Drug: Sonidegib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonidegib (200 mg single dose)
Trial: 27277189
Drug: Sonidegib with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonidegib with esomeprazole (40 mg pre-treatment for 5 days, combination on day 6)
Trial: 18711187
Drug: Reinduction chemotherapy
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinduction chemotherapy (three 35-day blocks) for early relapse (ER)
Trial: 18711187
Drug: Reinduction chemotherapy
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinduction chemotherapy (three 35-day blocks) for late relapse (LR)
Trial: 18711187
Drug: Reinduction chemotherapy
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinduction chemotherapy (three 35-day blocks) for MRD-negative patients
Trial: 18711187
Drug: Reinduction chemotherapy
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinduction chemotherapy (three 35-day blocks) for MRD-positive patients
Trial: 18711187
Drug: Reinduction chemotherapy
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinduction chemotherapy (three 35-day blocks)
Trial: 10472596
Drug: Azithromycin (AZM)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (AZM) 500 mg/24 h for 3 days
Trial: 10472596
Drug: Cefuroxime (ACF)
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime (ACF) 500 mg/12 h for 10 days
Trial: 6138592
Drug: Azathioprine and
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine and steroids (Control)
Trial: 30667279
Drug: rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rivaroxaban 2.5 mg twice daily plus aspirin
Trial: 24392086
Drug: Preventive medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive medication for osteoporosis (specific medication not detailed)
Trial: 21725374
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy with auto-SCT (Arm B)
Trial: 21725374
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (Arm A)
Trial: 19652123
Drug: Olanzapine plus
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine plus sertraline (target doses of 15 to 20 mg of olanzapine per day plus masked sertraline at 150 to 200 mg per day)
Trial: 19652123
Drug: Olanzapine plus
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine plus placebo (target doses of 15 to 20 mg of olanzapine per day plus masked placebo)
Trial: 19652123
Drug: Olanzapine plus
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine plus sertraline and Olanzapine plus placebo
Trial: 8971314
Drug: Paracetamol elixir
RxNorm normalized name: Soul Pattinson Childrens Paracetamol Elixir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol elixir 40 mg/kg preoperatively (Group A)
Trial: 8971314
Drug: Paracetamol suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol suppositories 40 mg/kg after induction of anaesthesia (Group B)
Trial: 8971314
Drug: Paracetamol elixir
RxNorm normalized name: Soul Pattinson Childrens Paracetamol Elixir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol elixir (Group A)
Trial: 8971314
Drug: Paracetamol suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol suppositories (Group B)
Trial: 8971314
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with plasma paracetamol concentrations above 0.07 mmol/l
Trial: 30958329
Drug: Neck stabilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neck stabilization exercise and breathing retraining exercise (15 minutes each) in addition to rehabilitation exercise treatment.
Trial: 30958329
Drug: Breathing retraining
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breathing retraining exercise (30 minutes) in addition to rehabilitation exercise treatment.
Trial: 19766902
Drug: Folate supplementation
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate supplementation (5mg daily for 8 weeks)
Trial: 18044061
Drug: Anticholinergic bronchodilator
RxNorm normalized name: BRONCHODILATORS,ANTICHOLINERGIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic bronchodilator
Trial: 18044061
Drug: β-agonist bronchodilator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-agonist bronchodilator
Trial: 18044061
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of β-agonists and anticholinergics
Trial: 18044061
Drug: β-agonists added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-agonists added to anticholinergic or inhaled corticosteroid use
Trial: 15110023
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 100 mg
Trial: 7950288
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation (6 x 50 mg Fe2+ aspartate/day)
Trial: 7950288
Drug: Parenteral iron
RxNorm normalized name: Iron, parenteral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral iron therapy (0.75 mg/kg BW complex‐bound Fe3+ once a week by infusion)
Trial: 2891224
Drug: famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 40 mg once at night
Trial: 31420120
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin for 21 consecutive days
Trial: 25205008
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for insomnia plus treatment as usual (TAU)
Trial: 16505644
Drug: L-alanyl-L-glutamine dipeptide
RxNorm normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-alanyl-L-glutamine dipeptide (0.5 g.kg‐1.day‐1; Ala‐Gln group, n=58)
Trial: 16505644
Drug: L-alanine+L-proline (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-alanine+L-proline (control group, n=56)
Trial: 14768792
Drug: Mega-dose methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mega-dose methylprednisolone (MDMP) 30 mg/kg/d for 3 days and 20 mg/kg/d for 4 days
Trial: 14768792
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) 1 g/kg/d for 2 days
Trial: 4038511
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous metoclopramide (MCP) at a dose of 2 mg/kg IV for three doses
Trial: 4038511
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high-dose intravenous metoclopramide (MCP) and intravenous dexamethasone (DXM) at a dose of 20 mg IV for three doses
Trial: 23973522
Drug: Fesoterodine 4
RxNorm normalized name: fesoterodine 4 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg once daily for 4 weeks, with possible increase to 8 mg based on investigator discussion.
Trial: 23973522
Drug: Fesoterodine 8
RxNorm normalized name: fesoterodine 8 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 8 mg once daily (with option to decrease to 4 mg).
Trial: 18588561
Drug: salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmeterol/fluticasone propionate combination
Trial: 15966221
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy group (n=7) with novel arterial infusion regimen using cisplatin (CDDP) and 5‐fluorouracil (5‐FU)
Trial: 15966221
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=8) with no adjuvant chemotherapy
Trial: 15966221
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy group (n=7)
Trial: 7773582
Drug: High-dose oral/intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral/intravenous fluconazole (400 mg daily)
Trial: 7773582
Drug: Oral nystatin
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nystatin plus miconazole inhalations
Trial: 2275309
Drug: Topical zinc
RxNorm normalized name: bacitracin topical zinc compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical zinc oxide
Trial: 7404497
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) heparin
Trial: 7404497
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) heparin
Trial: 24298982
Drug: Cylindrical implant
RxNorm normalized name: Imperata cylindrica root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cylindrical implant
Trial: 24298982
Drug: Conical/cylindrical implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conical/cylindrical implant
Trial: 19345510
Drug: Acamprosate (1998
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (1998 mg daily) during Detoxification Phase (5-14 days)
Trial: 19345510
Drug: Acamprosate (1998
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (1998 mg daily) during Rehabilitation Phase (after detoxification)
Trial: 11170991
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of RTS,S/SBAS2